everolimus 2.5mg tablets
a a h pharmaceuticals ltd - everolimus - oral tablet - 2.5mg
everocan everolimus 1 mg tablet bottle pack
pharmacor pty ltd - everolimus, quantity: 1 mg - tablet, uncoated - excipient ingredients: lactose; hypromellose; acetone; lactose monohydrate; ethanol absolute; magnesium stearate; crospovidone; butylated hydroxytoluene - everolimus is indicated for the prophylaxis of organ rejection in adult patients at mild to moderate immunological risk receiving an allogeneic renal or cardiac transplant and in adult patients receiving an allogeneic hepatic transplant (see section 4.4 special warnings and precautions for use).
everocan everolimus 0.25 mg tablet blister pack
pharmacor pty ltd - everolimus, quantity: 0.25 mg - tablet, uncoated - excipient ingredients: ethanol absolute; lactose monohydrate; butylated hydroxytoluene; magnesium stearate; lactose; acetone; hypromellose; crospovidone - everolimus is indicated for the prophylaxis of organ rejection in adult patients at mild to moderate immunological risk receiving an allogeneic renal or cardiac transplant and in adult patients receiving an allogeneic hepatic transplant (see section 4.4 special warnings and precautions for use).
everocan everolimus 1 mg tablet blister pack
pharmacor pty ltd - everolimus, quantity: 1 mg - tablet, uncoated - excipient ingredients: lactose; acetone; butylated hydroxytoluene; magnesium stearate; ethanol absolute; lactose monohydrate; crospovidone; hypromellose - everolimus is indicated for the prophylaxis of organ rejection in adult patients at mild to moderate immunological risk receiving an allogeneic renal or cardiac transplant and in adult patients receiving an allogeneic hepatic transplant (see section 4.4 special warnings and precautions for use).
everocan everolimus 0.75 mg tablet blister pack
pharmacor pty ltd - everolimus, quantity: 0.75 mg - tablet, uncoated - excipient ingredients: hypromellose; butylated hydroxytoluene; ethanol absolute; acetone; crospovidone; lactose; magnesium stearate; lactose monohydrate - everolimus is indicated for the prophylaxis of organ rejection in adult patients at mild to moderate immunological risk receiving an allogeneic renal or cardiac transplant and in adult patients receiving an allogeneic hepatic transplant (see section 4.4 special warnings and precautions for use).
everocan everolimus 0.5 mg tablet blister pack
pharmacor pty ltd - everolimus, quantity: 0.5 mg - tablet, uncoated - excipient ingredients: lactose; ethanol absolute; magnesium stearate; lactose monohydrate; hypromellose; crospovidone; acetone; butylated hydroxytoluene - everolimus is indicated for the prophylaxis of organ rejection in adult patients at mild to moderate immunological risk receiving an allogeneic renal or cardiac transplant and in adult patients receiving an allogeneic hepatic transplant (see section 4.4 special warnings and precautions for use).
everolimus eg 2.5 mg tabl.
eg sa-nv - everolimus 2,5 mg - tablet - 2,5 mg - everolimus 2.5 mg - everolimus
everolimus eg 5 mg tabl.
eg sa-nv - everolimus 5 mg - tablet - 5 mg - everolimus 5 mg - everolimus
everolimus eg 10 mg tabl.
eg sa-nv - everolimus 10 mg - tablet - 10 mg - everolimus 10 mg - everolimus
everolimus krka 10 mg tabl.
krka d.d. novo mesto d.d. - everolimus 10 mg - tablet - 10 mg - everolimus 10 mg - everolimus